On November 14, 2023 Starpharma (ASX: SPL, OTCQX: SPHRY) reported that it will present at the Bell Potter Healthcare Conference, a virtual investor conference that showcases Australia’s leading healthcare companies to institutional investors and Bell Potter’s retail network (Press release, Starpharma, NOV 14, 2023, View Source;mc_eid=bf52dd3418 [SID1234637576]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Starpharma will present an overview of the business, with a focus on recent milestones, including the positive clinical data reported for DEP cabazitaxel1 and DEP irinotecan2 in multiple cancers, as well as the positive preclinical data from the DEP radiotheranostics programs.

The Bell Potter Healthcare Conference presentation is appended.